John Milad

John E. Milad is a seasoned healthcare industry professional with over 25 years of experience in leadership, investment, and advisory roles within the life sciences and medical technology sectors.12 He currently serves as the CEO of ERS Genomics, a company that licenses the Nobel Prize-winning CRISPR/Cas9 gene editing technology.23

Career Highlights

Leadership Roles::

• CEO of ERS Genomics (May 2024 - Present)3
• CEO of Quanta Dialysis Technologies (January 2014 - July 2022)1
• CFO of Nitec Pharma3

Investment Experience::

• Partner & Co-Head of Healthcare Ventures at Downing LLP (January 2023 - Present)14
• Investment Director at NBGI Ventures (March 2009 - December 2013)1
• Roles at Atlas Venture and Kirkland Investors2

Board Positions::

• Board Member at Kidney Research UK1
• Board Member at Otivio AS1
• Previously served on boards of companies like Cellnovo Group, Advanced Cardiac Therapeutics, and Symetis1

Achievements and Recognition

• Led Quanta Dialysis Technologies in developing and launching an award-winning portable hemodialysis system3
• Raised a record-breaking $245 million private funding round for Quanta3
• Named in the Sunday Times Maserati List as one of the UK's "Top 100 Game Changing Innovators and Entrepreneurs"3
• Recipient of awards such as Industrial Product Design of the Year (2018) and New Product of the Year (2019)1

Education and Additional Roles

• Graduated from The University of Chicago with a BA (1990-1994)1
• Business mentor at the Royal Academy of Engineering's accelerator program12
• Served on the i4i selection panel for translational research at the National Institute for Health and Care Research (NIHR)3

John E. Milad's extensive experience in healthcare innovation, venture capital, and executive leadership positions him as a prominent figure in the life sciences and medical technology sectors.